# C_2014371EN.01002101.xml

| 18.10.2014 | EN | Official Journal of the European Union | C 371/21 |
| --- | --- | --- | --- |

18.10.2014

EN

Official Journal of the European Union

C 371/21

---

Prior notification of a concentration

(Case M.7326 — Medtronic/Covidien)

(Text with EEA relevance)

(2014/C 371/14)

| 1. | On 10 October 2014 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Medtronic, Inc. (‘Medtronic’, US) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Covidien plc (‘Covidien’, Ireland) by way of a public bid. |
| --- | --- |

1.

On 10 October 2014 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Medtronic, Inc. (‘Medtronic’, US) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Covidien plc (‘Covidien’, Ireland) by way of a public bid.

1

| 2. | The business activities of the undertakings concerned are:
  —   for Medtronic: development of medical technology and the provision of products, therapies and services treating a variety of medical conditions, including cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions,
  —   for Covidien: development, manufacturing and sale of a diverse range of medical device and supply products, including for laparoscopic surgery, electrosurgery, biosurgery and vascular therapies. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for Medtronic: development of medical technology and the provision of products, therapies and services treating a variety of medical conditions, including cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions,

for Medtronic

—   for Covidien: development, manufacturing and sale of a diverse range of medical device and supply products, including for laparoscopic surgery, electrosurgery, biosurgery and vascular therapies.

for Covidien

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7326 — Medtronic/Covidien, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7326 — Medtronic/Covidien, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---